Results 281 to 290 of about 4,166,507 (358)

Key role for inhibins in effective T cell activation, migration and Th17 differentiation

FEBS Open Bio, EarlyView.
Activins/inhibins modulate immune responses. Here, we show that inhibins can be produced very early after T cell activation and can act in an autocrine way, favoring Th1 versus Th17 differentiation and CCL19/CCL21 mediated migration. Recombinant inhibin A can restore the Th1/Th17 balance, highlighting the role of inhibins as key regulators of T cell ...
Sandra Ortega‐Francisco, Roxana Olguín‐Alor, Lizbeth Bolaños‐Castro, Alexandra Morales‐Cruz, Marisol De La Fuente‐Granada, Gloria Soldevila   +5 more
wiley   +1 more source

Drug development and testing in relation to cell migration and chimerism [PDF]

, 1993
Demetris, AJ, Giorda, R, Murase, N, Starzl, TE, Trucco, M, Valdivia, L   +5 more
core  

Recent Advances in Drug Development for Hair Loss. [PDF]

Int J Mol Sci
Kim J, Song SY, Sung JH.
europepmc   +1 more source

Development of Anti-Emetic and Anti-Motion Sickness Drugs using Suncus murinus.

, 1991
Norio Matsuki
openalex   +1 more source

Transcriptional regulation of neuropeptide receptors underlies context‐dependent adaptation in Drosophila melanogaster

FEBS Open Bio, EarlyView.
Under environmental changes, the expression level of neuropeptide (NP) and neuropeptide receptor (NPR) genes changes to confer context‐dependent adaptation to the model organism Drosophila melanogaster. Through finding more regulatory elements in the NPR genes in comparison with their ligands (NPs), we found that NPR‐biased transcriptional regulation ...
SeungHeui Ryu, Yanan Wei, Zekun Wu, Tianmu Zhang, DoHoon Lee, Hadi Najafi, Woo Jae Kim   +6 more
wiley   +1 more source

Toward routine utilisation of native mass spectrometry as an enabler of contemporary drug development. [PDF]

RSC Med Chem
Sternicki LM, Poulsen SA.
europepmc   +1 more source

Report on the 2nd MObility for Vesicle research in Europe (MOVE) symposium—2024

FEBS Open Bio, EarlyView.
The 2nd MObility for Vesicle research in Europe (MOVE) Symposium in Belgrade brought over 280 attendees from 28 countries to advance extracellular vesicle (EV) research. Featuring keynotes, presentations, and industry sessions, it covered EV biogenesis, biomarkers, therapies, and manufacturing.
Dorival Mendes Rodrigues‐Junior, Michaela Kocholata, Marilena E. Lekka, Olga Janouskova, Moran Yadid, Maja Kosanovic   +5 more
wiley   +1 more source

Drug development for leukemia: comprehensive analysis of clinical trials from first report to drug approval. [PDF]

Blood Adv
Tjioe KC, Miranda-Galvis M, Mamouni K, Freitas T, Sharara M, Santellano B, Guillén-Lopez C, Cortes JE.   +7 more
europepmc   +1 more source

Identification of amino acids essential for angulin‐1/3 binding of the tricellular tight junction binder, angubindin‐1

FEBS Open Bio, EarlyView.
Angubindin‐1 binds angulin‐1/‐3 at tricellular tight junctions, enhancing intestinal macromolecule permeation. Alanine scanning identified six essential residues (L562, L598, E638, V640, Y643, and K644) of angubindin‐1 critical for binding to angulin‐1/‐3 and permeation‐enhancing activity, providing insights for the development of targeted noninvasive ...
Taiki Kuzu, Yumi Iwashita, Keisuke Tachibana, Itsuki Nishino, Yuki Niwa, Atsuko Uyeda, Kazuki Matsuo, Masahiro Nagahama, Masuo Kondoh   +8 more
wiley   +1 more source

Progress in structure-based drug development targeting chemokine receptors. [PDF]

Front Pharmacol
Wang J, Qu C, Xiao P, Liu S, Sun JP, Ping YQ.   +5 more
europepmc   +1 more source